SureTrader Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: buythebuy
Search This Board:
Last Post: 6/26/2016 1:54:00 PM - Followers: 170 - Board type: Free - Posts Today: 10


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Statement of Ownership (sc 13g) 06/21/2016 06:04:09 AM
USRM News: Statement of Ownership (sc 13g) 06/08/2016 06:06:14 AM
USRM News: Statement of Ownership (sc 13g) 05/26/2016 11:42:40 AM
USRM News: Quarterly Report (10-q) 05/04/2016 04:05:37 PM
USRM News: Statement of Ownership (sc 13g) 04/28/2016 04:39:00 PM
#17044  Sticky Note USRM LATEST PRESS RELEASE! buythebuy 06/25/16 11:39:49 AM
#17054   These series of posts is an attempt to Poor Man - 06/26/16 01:54:00 PM
#17053   One thing I did find interesting about USRM buythebuy 06/26/16 01:10:31 PM
#17052   USRM could come through big after trials. buythebuy 06/26/16 12:56:29 PM
#17051   Thanks!! This could be very interesting moneybagsclay 06/26/16 12:53:47 PM
#17050   You are welcome. USRM is using the bodies buythebuy 06/26/16 12:53:21 PM
#17049   For drugs and certain procedures it can take buythebuy 06/26/16 12:51:45 PM
#17048   When clinical trials are over this could explode !! moneybagsclay 06/26/16 12:06:59 PM
#17047   Usrm looks undervalued imo moneybagsclay 06/26/16 12:05:16 PM
#17046   Thanks for posting usrm moneybagsclay 06/26/16 12:03:40 PM
#17045   I would like to know how long these moneybagsclay 06/26/16 12:02:16 PM
#17044   USRM LATEST PRESS RELEASE! buythebuy 06/25/16 11:39:49 AM
#17043   USRM Short report. buythebuy 06/25/16 08:17:14 AM
#17042   USRM Trader's cheat sheet! buythebuy 06/25/16 08:14:48 AM
#17041   USRM Times and Sales data buythebuy 06/25/16 08:11:22 AM
#17040   USRM could be on the verge of a buythebuy 06/25/16 08:09:19 AM
#17039   1.55 CENTS, ANOTHER NEW RECORD LOW Hornet Driver 06/24/16 03:15:24 PM
#17038   B*A*N*K*R*U*P*T*C*Y Tourbillon7575 06/24/16 09:08:06 AM
#17037   If every time I listened to your recommendation Poor Man - 06/23/16 06:39:20 PM
#17036   Chart is looking like a good setup. .10-.25 EquityElite 06/22/16 06:11:10 PM
#17035   ANOTHER SEC 13G filed..shows MASSIVE DILUTION Hornet Driver 06/21/16 08:04:46 PM
#17034   Good time to enter ... Tourbillon7575 06/20/16 10:49:18 AM
#17033   2.5 CENTS, ANOTHER new ALL TIME LOW.. Hornet Driver 06/15/16 04:24:33 PM
#17032   Bid hit SUB 3 CENTS, new ALL TIME LOW Hornet Driver 06/14/16 04:32:01 PM
#17031   To my regret, soon bankruptcy! Tourbillon7575 06/06/16 05:29:30 PM
#17030   Market cap = 166.000 USD. Ah ah Tourbillon7575 06/06/16 05:27:04 PM
#17029   Soon "1 CENT, ANOTHER new ALL TIME LOW Tourbillon7575 06/06/16 05:24:16 PM
#17028   3 CENTS, ANOTHER new ALL TIME LOW - Hornet Driver 06/03/16 01:56:04 PM
#17027   4.5 CENTS, ANOTHER new, all, all TIME LOW Hornet Driver 05/20/16 02:10:52 PM
#17026   Dilution has been STAGGERING, still on-going: Hornet Driver 05/13/16 01:55:05 PM
#17025   Correction: Got the timing wrong. The number of common Poor Man - 05/08/16 10:00:23 PM
#17024   "As of May 4, 2016, there were 5,042,656 Poor Man - 05/05/16 05:57:05 PM
#17023   U.S. Stem Cell, Inc. Reports Positive Results for Investaholic33 05/05/16 05:08:13 PM
#17022   This company is a POS garym 05/04/16 09:06:25 AM
#17021   SEC 13G shows MASSIVE on-going DILUTION: Hornet Driver 04/30/16 09:49:01 PM
#17020 EquityElite 04/21/16 07:45:46 AM
#17019   Hmm it has been a while... too long. Investaholic33 04/20/16 09:49:18 PM
#17018   Blog is out? EquityElite 04/20/16 03:54:04 PM
#17017   5 CENTS, ANOTHER RECORD ALL, ALL TIME LOW ! Hornet Driver 04/18/16 10:49:53 AM
#17016   Mr Tomas should be in jail for what toddski 04/11/16 08:42:26 PM
#17015   9 CENTS, ANOTHER record ALL, ALL TIME LOW ! Hornet Driver 04/11/16 02:43:36 PM
#17014   How are the CD lenders doing on this? EquityElite 04/11/16 11:42:34 AM
#17013   This scam should be shut down and the Ringohalfcan 03/31/16 02:18:52 PM
#17012   Selling shares to the end. With no Ringohalfcan 03/31/16 02:06:12 PM
#17011   Yes aaaaaannnyyyyttthhing andyshow 03/28/16 03:27:22 PM
#17010   Wish we would hear aaannyyything from the company. Investaholic33 03/23/16 09:59:14 PM
#17009   .12 52W low? EquityElite 03/23/16 09:29:03 PM
#17008   17 CENTS, another NEW ALL TIME LOW TODAY Hornet Driver 03/21/16 11:01:36 PM
#17007   What's happening ? EquityElite 03/16/16 08:51:31 PM
#17006   U.S. Stem Cell reported $3.9 million in aggregate Poor Man - 03/12/16 12:07:12 AM
#17005   What a dog of a stock Poor Man - 03/10/16 07:38:41 PM